Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis

Seeto, Alexander H.; Tadrous, Mina; Gebre, Abadi Kahsu; Lewis, Joshua R.; Fink, Howard A; Ebeling, Peter R.; Rodríguez, Alexander J.

doi:10.1016/j.bone.2022.116610

Cited by 12 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular risk seems to be highest in the group with highest fracture risk [55], which in part may be due to genetic factors connecting the risks for cardiovascular disease and osteoporosis [56]. Moreover, a very recent systematic review and meta-analysis revealed no pooled direct and indirect evidence that osteoporosis treatments significantly increase the cardiovascular risk [57]. Others report about protective properties of bisphosphonates with respect to cardiovascular complications [58].…”

Section: Conclusion For Clinical Practicementioning

confidence: 99%

Recommendations for the Pharmacological Treatment of Osteoporosis – Update 2023 of the German Osteoporosis Guideline

et al. 2023

View full text Add to dashboard Cite

Aim The German osteoporosis guideline was updated on the basis of a systematic literature review and through a structured consensus process by an interdisciplinary, international (Germany, Austria, Switzerland) expert group representing the 20 member societies of the Joint Osteological Association (DVO) and patient advocacy organizations (BfO). This manuscript summarizes the changes in the German osteoporosis guideline with regard to pharmacological interventions and offers pragmatic pathways for implementation. Method Systematic literature search and structured consensus building according to AWMF regulations. Results The sclerostin antibody romosozumab was adopted into the guideline. In addition, the effectiveness of teriparatide was re-evaluated. For both bone anabolic agents evidence from randomized trials underlined a superiority over oral bisphosphonates with regard to fracture risk reduction. Between the antiresorptive treatments, differences regarding superiority/inferiority could only be shown with respect to surrogate parameters, not with regard to fractures. Data about the duration of treatment of all available drugs is limited. All non-bisphosphonate treatments require follow-up treatment. Conclusion An individualized treatment concept should be developed in a shared decision process, including a bone anabolic-first strategy in high-risk patients. Recommendations on treatment duration, drug holidays and sequential strategies should be considered.

show abstract

Section: Conclusion For Clinical Practicementioning

confidence: 99%

Recommendations for the Pharmacological Treatment of Osteoporosis – Update 2023 of the German Osteoporosis Guideline

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Drug treatment is a common treatment for OP, with the purpose of increasing individual bone mass and bone density 6 . However, the long‐term use of such drugs has uncertain long‐term efficacy and side effects, such as an increased risk of cardiovascular events 7–9 . Therefore, researchers gradually began to explore other drugs that can improve OP with few side effects.…”

Section: Introductionmentioning

confidence: 99%

“… 6 However, the long‐term use of such drugs has uncertain long‐term efficacy and side effects, such as an increased risk of cardiovascular events. 7 , 8 , 9 Therefore, researchers gradually began to explore other drugs that can improve OP with few side effects. In the population with OP, the reduction in bone density and the reduction in fracture healing ability may be related to the reduction in bone marrow mesenchymal stem cell (MSC) proliferation and osteogenic differentiation ability.…”

Section: Introductionmentioning

confidence: 99%

Effects of tetrahedral DNA nanostructures on the treatment of osteoporosis

Cui,

Yang,

Dou

et al. 2024

Cell Proliferation

View full text Add to dashboard Cite

Osteoporosis (OP) is a common disease characterized by bone loss and bone tissue microstructure degradation. Drug treatment is a common clinical treatment that aims to increase bone mass and bone density. Tetrahedral DNA nanostructures (TDNs) are three‐dimensional tetrahedral frames formed by folding four single‐stranded DNA molecules, which have good biological safety and can promote bone regeneration. In this study, a mouse model of OP was established by ovariectomy (OVX) and TDN was injected into the tail vein for 8 weeks. We found that ovariectomized mice could simulate some physiological changes in OP. After treatment with TDNs, some of this destruction in mice was significantly improved, including an increase in the bone volume fraction (BV/TV) and bone trabecular number (Tb. N), decrease in bone separation (Tb. SP), reduction in the damage to the mouse cartilage layer, reduction in osteoclast lacunae in bone trabecula, and reduction in the damage to the bone dense part. We also found that the expression of ALP, β‐Catenin, Runx2, Osterix, and bone morphogenetic protein (BMP)2 significantly decreased in OVX mice but increased after TDN treatment. Therefore, this study suggests that TDNs may regulate the Wnt/β‐Catenin and BMP signalling pathways to improve the levels of some specific markers of osteogenic differentiation, such as Runx2, ALP, and Osterix, to promote osteogenesis, thus showing a therapeutic effect on OP mice.

show abstract

Romosozumab: Clinical Applications, Outcomes, and Perspectives in Osteoporosis Treatment

Brunetti

2023

Tissue Repair and Reconstruction

View full text Add to dashboard Cite

Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis

Cited by 12 publications

References 30 publications

Recommendations for the Pharmacological Treatment of Osteoporosis – Update 2023 of the German Osteoporosis Guideline

Recommendations for the Pharmacological Treatment of Osteoporosis – Update 2023 of the German Osteoporosis Guideline

Effects of tetrahedral DNA nanostructures on the treatment of osteoporosis

Romosozumab: Clinical Applications, Outcomes, and Perspectives in Osteoporosis Treatment

Contact Info

Product

Resources

About